MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –


– Initial Results from Correlative Studies Demonstrate On-target...

Related Keywords

United States ,American ,Matthews Davids ,Davidm Urso , ,American Society Of Hematology ,Harvard Medical School ,Nasdaq ,Pharma Inc ,Clinical Research ,Linkedin ,Dana Farber Cancer Institute ,Division Of Lymphoma ,American Society ,Annual Meeting ,Ongoing Phase ,Evaluating Voruciclib ,B Cell Lymphoma ,Acute Myeloid Leukemia ,Acute Myeloid Leukemias ,Investigational Therapies ,Excluding Transplantation ,Associate Professor ,Pacific Time ,Plus Venetoclax Combination ,Markets ,